ArticleResearch (Washington, D.C.)2024
Remodeling Intestinal Microbiota Alleviates Severe Combined Hyperlipidemia-Induced Nonalcoholic Steatohepatitis and Atherosclerosis in LDLR
Article in Research (Washington, D.C.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Gut microbiota regulate atherosclerosis via the gut-vascular axis: a scoping review of mechanisms and therapeutic interventions.Frontiers in microbiology · 2025Pooled it
- Trial
- Metabolic Perspective on Atherosclerosis: Macrophage Reprogramming and Novel Therapeutic Targets.Journal of the American Heart Association · 2026Review
- From Respiration to Secondary Metabolism: A Heme A Synthase-Mediated Regulatory Network Expands Indolizidine Chemical Space in Fungi.Research (Washington, D.C.) · 2026Article
- Dietary Index for Gut Microbiota and All-Cause Mortality in CKM Syndrome: Evidence of a JShaped Association and Partial Mediation by DII and CDAI.Endocrine, metabolic & immune disorders drug targets · 2026Article
- The Gut Microbiota: Emerging Evidence in Autoimmune and Inflammatory Diseases.Research (Washington, D.C.) · 2026Review
- KIF13B Attenuates Sepsis-Induced Myocardial Dysfunction through the Stabilization of PLIN5.Research (Washington, D.C.) · 2026Article
- Link between Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Diseases.Research (Washington, D.C.) · 2026Review
- Isoginkgetin, a natural biflavonoid from Ginkgo biloba, inhibits inflammatory response in endothelial cells via suppressing NF-κB activation.Acta pharmacologica Sinica · 2025Article
- The current findings on the gut-liver axis and the molecular basis of NAFLD/NASH associated with gut microbiome dysbiosis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- A multicellular self-organized probiotic platform for oral delivery enhances intestinal colonization.Nature communications · 2025Article
- Article
- Bariatric Surgery Impact on Women with Polycystic Ovary Syndrome: A Prospective Cohort Study.Research (Washington, D.C.) · 2025Review
- Association between dietary index for gut microbiota and cardiovascular-kidney-metabolic syndrome: a population-based study.Frontiers in nutrition · 2025Article
- Fat-1 Ameliorates Metabolic Dysfunction-Associated Fatty Liver Disease and Atherosclerosis through Promoting the Nuclear Localization of PPARα in Hamsters.Research (Washington, D.C.) · 2025Article
- Prioritization of Lipid Metabolism Targets for the Diagnosis and Treatment of Cardiovascular Diseases.Research (Washington, D.C.) · 2025Article
- Associations between dietary microbe intake and mortality risk in individuals with sleep disorders: Evidence from NHANES.PloS one · 2025Article
- Alanine Derived fromResearch (Washington, D.C.) · 2025Article
- A natural small molecule isoginkgetin alleviates hypercholesterolemia and atherosclerosis by targeting ACLY.Theranostics · 2025Article
- Multi-omics analysis of Au@Pt nanozyme for the modulation of glucose and lipid metabolism.Journal of nanobiotechnology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combined hyperlipidemia (CHL) manifests as elevated cholesterol and triglycerides, associated with fatty liver and cardiovascular diseases. Emerging evidence underscores the crucial role of the intestinal microbiota in metabolic disorders. However, the potential therapeutic viability of remodeling the intestinal microbiota in CHL remains uncertain. In this study, CHL was induced in low-density lipoprotein receptor-deficient (LDLR
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.